抗ASFV p72蛋白的单克隆抗体、其抗原表位肽及应用
By using the natural conformation p72 protein as an immunogen and combining it with hybridoma cell fusion screening technology, a high-affinity monoclonal antibody 3B9 was obtained, which solved the problems of insufficient antibody specificity and unclear epitopes in ASFV detection, and achieved high sensitivity and high specificity ASFV detection.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- LONGHU LAB
- Filing Date
- 2026-04-24
- Publication Date
- 2026-07-17
AI Technical Summary
In existing ASFV detection and diagnostic technologies, the correct folding of the p72 protein depends on the assistance of the molecular chaperone B602L. The protein obtained from prokaryotic expression often exists in the form of inclusion bodies, which results in insufficient antibody specificity, low affinity, unclear recognition epitopes, and complex and costly preparation processes, making it difficult to meet the needs of rapid detection and large-scale application.
Using the natural conformation of p72 protein as an immunogen, combined with hybridoma cell fusion screening and epitope localization technology, a high-affinity monoclonal antibody 3B9 was obtained. This antibody specifically recognizes the conserved linear epitope of p72 protein, establishing a highly sensitive and specific detection method.
It achieves high sensitivity and high specificity detection of ASFV antigen, clarifies epitope information, and the antibody has high titer, high affinity and good stability, reducing the risk of false positives and making it suitable for long-term storage and large-scale application.
Smart Images
Figure CN122404541A_ABST